Skip to main content
. 2022 Oct 28;14(21):5306. doi: 10.3390/cancers14215306
Dabrafenib Small-molecule, ATP-competitive inhibitor of the rapidly accelerated fibrosarcoma (RAF) kinases, especially mutant BRAF.
Dacomitinib Small-molecule, irreversible inhibitor of the pan-human epidermal growth factor receptor (HER) family.
Doxorubicin and epirubicin Chemotherapeutic agents belonging to the class of anthracyclines, acting by multiple mechanisms including (1) intercalating between base pairs in the DNA helix, (2) inhibiting topoisomerase 2, and (3) forming oxygen free radicals.
Everolimus Allosteric inhibitor of the mammalian target of rapamycin (mTOR), inhibiting the mTOR functional complex mTORC1.
Fulvestrant Selective estrogen receptor downregulator or degrader, competitively binding to estrogen receptors and promoting their degradation.
Infigratinib Pan-inhibitor of human fibroblast growth factor receptors (FGFRs).
JQ1 Small molecule, competitive inhibitor of bromodomain-containing 4 (BRD4), an epigenetic reader acting as transcriptional regulator.
Lapatinib Small molecule, ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).
Neratinib Small molecule, irreversible inhibitor of EGFR and HER2.
Palbociclib Cyclin-dependent kinase 4 and 6 inhibitor, preventing retinoblastoma (Rb) protein phosphorylation and leading to cell cycle arrest.
Ponatinib Small molecule, multitargeted tyrosine kinase inhibitor, inhibiting, among others, BCR-ABL, vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), TEK Receptor Tyrosine Kinase (TIE2), FMS-like tyrosine kinase 3 (FLT3), KIT, and REarranged during Transfection (RET).
Selumetinib Small molecule, allosteric inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2.
SHP099 Small molecule, allosteric inhibitor of Srchomology-2-domain-containing PTP 2 (SHP2).
Sorafenib Small molecule, multitargeted tyrosine kinase inhibitor, inhibiting, among others, RAF, VEGFR 1/2/3, platelet-derived growth factor receptor (PDGFR) beta, KIT, FLT3, FGFR1, and RET.
Tamoxifen Selective estrogen receptor modulator (SERM), competitively inhibiting the binding of estradiol to estrogen receptors.
Trametinib Small molecule, allosteric inhibitor of MEK1 and MEK2.
Trastuzumab Recombinant humanized monoclonal antibody targeting the extracellular domain of HER2.
Tucatinib ATP-competitive, small molecule inhibitor of HER2.
Ulixertinib Small molecule, ATP-competitive inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2.
Vemurafenib ATP-competitive, small-molecule inhibitor of mutant BRAF, including BRAF(V600E).